Press Releases
Historic Argyrol® Registration Acquired
United States Patent and Trademark Office assignment of world-reknowned mark Argyrol® registration held by Johnson & Johnson Pharmaceuticals, issued to Christine McKinney in 2001 after unchallenged USPTO process. Grandfather drug OTC Argyrol® Anti-Infective was manufactured by IOLAB PHARMACEUTICALS until 1992. Johnson & Johnson's IOLAB was acquired by Bausch & Lomb without transfer of license for manufacture of Argyrol® Anti-Infective. From the moment Argyrol® mark was awarded to McKinney based upon legal argument, the goal has been to make certain this valuable medicine remains available in commerce. Argyrol® Pharmaceuticals seeks a pharmaceutical channel partner for the responsibility to globally distribute Argyrol® Anti-Infective for a first aid, first line of defense for first response hygiene protocols against pathogenic and drug resistant strains of bacteria and viruses. Argyrol® and Argyrol® derivatives are drug regulatory compliant to distribute into global populations. Argyrol® Anti-Infective was mandated by the United States Surgeon General against the pandemic of influenza during the previous decade. Argyrol® Anti-Infective long had been listed as a World Health Organization Essentials Medicine. Argyrol® Anti-Infective products provide the most vigilent hygiene protocols against transmission of opportunistic communicable diseases.
Argyrol | Customer Service | Contact
All Material © Argyrol Pharmaceuticals
Call 1-657-208-3655